Intas Picks Up Global Rights To Meiji And Dong-A’s Stelara Biosimilar

Ustekinumab Deal – Which Excludes Certain Asian Markets – Is Worth More Than $100m

 
• By Dave Wallace

Japan’s Meiji Seika Pharma and Korea’s Dong-A have struck an exclusive licensing deal with Intas for global rights to the pair’s DMB-3115 proposed ustekinumab biosimilar to Stelara.

Globe Japan Korea World Space
Meiji and Dong-A take their ustekinumab biosimilar global with Intas • Source: Alamy

More from Biosimilars

More from Products